FDA approves GSK’s BLENREP (belantamab mafodotin-blmf) for …
BLENREP is GSK’s fifth major medicine approval in 2020 across areas of significant unmet medical need such as cancer, HIV and chronic kidney disease. This approval marks the …
GSK will pull Blenrep from US market after failed trial
5 days ago · GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the …
FDA approves GSK's Blenrep for advanced multiple myeloma
5 days ago · Blenrep (belantamab mafodotin) has been approved in patients who have received at least four therapies including an anti-CD38 such as Darzalex, a proteasome inhibitor and an …
GSK wins approval in Japan for Blenrep combination as myeloma …
23 hours ago · Blenrep combinations are currently under review in "all major markets globally", GSK said, including in the US with a prescription drug user fee act date of July 23, as well as …
Blenrep shows significant overall survival benefit, reducing the ... - GSK
Dec 9, 2024 · GSK plc (LSE/NYSE: GSK) today announced statistically significant and clinically meaningful overall survival (OS) results from a planned interim analysis of the DREAMM-7 trial …
Japan follows UK in GSK's comeback tour for Blenrep
21 hours ago · GSK has said it expects Blenrep to achieve peak annual sales of around £3 billion (nearly $4 billion). It also plans to continue working on Blenrep's comeback with the DREAMM …
GSK: Japan Approves Blenrep Combinations To Treat Relapsed
1 day ago · GSK noted that superior efficacy results from the pivotal DREAMM-7 and DREAMM-8 phase III trials in relapsed or refractory multiple myeloma support MHLW approval of Blenrep …
Blenrep (belantamab mafodotin) combinations approved by UK MHRA ... - GSK
Apr 17, 2025 · GSK plc (LSE/NYSE: GSK) today announced the authorisation of Blenrep by the Medicines and Healthcare products Regulatory Agency (MHRA).
Blenrep combinations accepted for review by the US FDA for the ... - GSK
Nov 25, 2024 · GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for …
GSK provides an update on Blenrep (belantamab mafodotin …
Nov 22, 2022 · Blenrep is a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies, including an anti …